Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dose Size and Dosing Frequency: Determination Methods

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.

American journal of clinical dermatology·2023

Same author

Challenges in the management of hereditary angioedema in urban and rural settings: Results of a United States survey.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2023

Same author

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2021

Same author

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.

Orphanet journal of rare diseases·2021

Same author

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.

Orphanet journal of rare diseases·2021

Same author

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.

The Journal of allergy and clinical immunology·2020

Search research articles

Related Experiment Video

Updated: May 14, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

HAE update: determining optimal patient specific therapy.

Richard G Gower¹

¹University of Washington, Marycliff Allergy Specialists, Spokane, WA 99204, USA. rgower@marycliffallergy.com

Allergy and Asthma Proceedings

|February 15, 2013

Summary

Hereditary angioedema (HAE) management requires personalized treatment plans. Available therapies for acute attacks and prophylaxis should be tailored to individual patient needs and preferences for optimal outcomes.

More Related Videos

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

Related Experiment Videos

Last Updated: May 14, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

Area of Science:

Immunology
Genetics
Pharmacology

Background:

Hereditary angioedema (HAE) is a rare autosomal dominant disorder.
It is characterized by recurrent swelling attacks due to C1 inhibitor deficiency or dysfunction.
Laryngeal attacks pose a life-threatening risk.

Purpose of the Study:

To provide an overview of current US-approved HAE treatments.
To outline strategies for individualizing therapy based on patient-specific factors.
To emphasize a patient-centered approach to HAE management.

Main Methods:

Literature search for HAE and available therapeutic modalities.
Evaluation of HAE guidelines and randomized controlled trials.
Review of FDA-approved acute and prophylactic treatments.

Main Results:

Several FDA-approved acute treatments exist: C1 inhibitor replacement, ecallantide, and icatibant.
Prophylactic options include attenuated androgens and C1 inhibitor.
All reviewed treatments demonstrated safety and efficacy in clinical trials.

Conclusions:

Optimal HAE therapy necessitates individualization based on attack frequency, severity, location, and quality of life burden.
Treatment decisions should consider patient preferences, occupation, and access to medical care.
A patient-centered approach is crucial for effective HAE management.